ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.5 Billion JPY | -50.95% |
| 2022 | 9.18 Billion JPY | -25.46% |
| 2021 | 12.32 Billion JPY | -10.36% |
| 2020 | 13.74 Billion JPY | 0.56% |
| 2019 | 13.67 Billion JPY | 5.4% |
| 2018 | 12.97 Billion JPY | 641.14% |
| 2017 | 1.75 Billion JPY | -30.0% |
| 2016 | 2.5 Billion JPY | -23.08% |
| 2015 | 3.25 Billion JPY | 482.44% |
| 2014 | 558 Million JPY | 381.03% |
| 2013 | 116 Million JPY | -90.12% |
| 2012 | 1.17 Billion JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 4.08 Billion JPY | -9.32% |
| 2024 Q2 | 3.66 Billion JPY | -10.28% |
| 2023 Q2 | 7.34 Billion JPY | -5.41% |
| 2023 FY | 4.5 Billion JPY | -50.95% |
| 2023 Q4 | 4.5 Billion JPY | -34.95% |
| 2023 Q3 | 6.92 Billion JPY | -5.72% |
| 2023 Q1 | 7.76 Billion JPY | -15.46% |
| 2022 Q3 | 9.62 Billion JPY | -4.18% |
| 2022 Q4 | 9.18 Billion JPY | -4.61% |
| 2022 FY | 9.18 Billion JPY | -25.46% |
| 2022 Q1 | 10.19 Billion JPY | -17.24% |
| 2022 Q2 | 10.04 Billion JPY | -1.46% |
| 2021 FY | 12.32 Billion JPY | -10.36% |
| 2021 Q3 | 12.47 Billion JPY | -0.99% |
| 2021 Q1 | 12.74 Billion JPY | -7.27% |
| 2021 Q4 | 12.32 Billion JPY | -1.2% |
| 2021 Q2 | 12.59 Billion JPY | -1.17% |
| 2020 Q2 | 12.77 Billion JPY | -0.19% |
| 2020 FY | 13.74 Billion JPY | 0.56% |
| 2020 Q4 | 13.74 Billion JPY | -1.08% |
| 2020 Q1 | 12.79 Billion JPY | -6.4% |
| 2020 Q3 | 13.89 Billion JPY | 8.81% |
| 2019 Q2 | 12.57 Billion JPY | -4.01% |
| 2019 Q3 | 11.69 Billion JPY | -6.96% |
| 2019 FY | 13.67 Billion JPY | 5.4% |
| 2019 Q1 | 13.09 Billion JPY | 0.96% |
| 2019 Q4 | 13.67 Billion JPY | 16.9% |
| 2018 Q4 | 12.97 Billion JPY | 1.53% |
| 2018 Q2 | 14.02 Billion JPY | 62.61% |
| 2018 Q1 | 8.62 Billion JPY | 392.86% |
| 2018 FY | 12.97 Billion JPY | 641.14% |
| 2018 Q3 | 12.77 Billion JPY | -8.91% |
| 2017 Q1 | 2.12 Billion JPY | -15.0% |
| 2017 FY | 1.75 Billion JPY | -30.0% |
| 2017 Q4 | 1.75 Billion JPY | 0.0% |
| 2017 Q3 | 1.75 Billion JPY | -17.65% |
| 2017 Q2 | 2.12 Billion JPY | 0.0% |
| 2016 Q1 | 2.87 Billion JPY | -11.54% |
| 2016 FY | 2.5 Billion JPY | -23.08% |
| 2016 Q2 | 2.87 Billion JPY | 0.0% |
| 2016 Q4 | 2.5 Billion JPY | 0.0% |
| 2016 Q3 | 2.5 Billion JPY | -13.04% |
| 2015 Q2 | 1.02 Billion JPY | 0.0% |
| 2015 Q1 | - JPY | -100.0% |
| 2015 Q4 | 3.25 Billion JPY | -0.88% |
| 2015 Q3 | 3.27 Billion JPY | 218.66% |
| 2015 FY | 3.25 Billion JPY | 482.44% |
| 2014 Q4 | 558 Million JPY | -4.94% |
| 2014 Q2 | 587 Million JPY | 0.0% |
| 2014 Q1 | - JPY | -100.0% |
| 2014 Q3 | 587 Million JPY | 0.0% |
| 2014 FY | 558 Million JPY | 381.03% |
| 2013 FY | 116 Million JPY | -90.12% |
| 2013 Q1 | 1.17 Billion JPY | 0.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2013 Q4 | 116 Million JPY | 0.0% |
| 2013 Q2 | - JPY | -100.0% |
| 2012 Q4 | 1.17 Billion JPY | -2.41% |
| 2012 Q3 | 1.2 Billion JPY | 0.0% |
| 2012 Q2 | 1.2 Billion JPY | 0.0% |
| 2012 FY | 1.17 Billion JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.23 Billion JPY | -265.963% |
| Takeda Pharmaceutical Company Limited | 4476.5 Billion JPY | 99.899% |
| Sumitomo Pharma Co., Ltd. | 133.36 Billion JPY | 96.622% |
| Shionogi & Co., Ltd. | 8.75 Billion JPY | 48.532% |
| Wakamoto Pharmaceutical Co.,Ltd. | - JPY | -Infinity% |
| Nippon Shinyaku Co., Ltd. | 1.15 Billion JPY | -291.059% |
| Kaken Pharmaceutical Co., Ltd. | - JPY | -Infinity% |
| Eisai Co., Ltd. | 134.77 Billion JPY | 96.657% |
| Morishita Jintan Co., Ltd. | 106 Million JPY | -4150.0% |
| Hisamitsu Pharmaceutical Co., Inc. | 76 Million JPY | -5827.632% |
| Mochida Pharmaceutical Co., Ltd. | - JPY | -Infinity% |
| Fuso Pharmaceutical Industries,Ltd. | 7.02 Billion JPY | 35.835% |
| Nippon Chemiphar Co., Ltd. | 13.34 Billion JPY | 66.24% |
| Tsumura & Co. | 54.37 Billion JPY | 91.715% |
| Kissei Pharmaceutical Co., Ltd. | - JPY | -Infinity% |
| Torii Pharmaceutical Co., Ltd. | 22 Million JPY | -20377.273% |
| Towa Pharmaceutical Co., Ltd. | 189.12 Billion JPY | 97.618% |
| Fuji Pharma Co., Ltd. | 11.92 Billion JPY | 62.219% |
| Zeria Pharmaceutical Co., Ltd. | 7.94 Billion JPY | 43.289% |
| KYORIN Holdings, Inc. | 435 Million JPY | -935.632% |
| Taiko Pharmaceutical Co.,Ltd. | 2.74 Billion JPY | -64.356% |
| Daito Pharmaceutical Co.,Ltd. | 4.66 Billion JPY | 3.513% |
| SymBio Pharmaceuticals Limited | - JPY | -Infinity% |
| MedRx Co., Ltd | - JPY | -Infinity% |
| Mizuho Medy Co.,Ltd. | - JPY | -Infinity% |
| Solasia Pharma K.K. | 27 Million JPY | -16585.185% |
| Modalis Therapeutics Corporation | 412.5 Million JPY | -992.121% |
| Sawai Group Holdings Co., Ltd. | 66.84 Billion JPY | 93.26% |
| Cyfuse Biomedical K.K. | 345 Million JPY | -1205.797% |
| Toho Holdings Co., Ltd. | 28.16 Billion JPY | 84.006% |
| Koa Shoji Holdings Co.,Ltd. | 1.59 Billion JPY | -183.087% |